Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis

In the Research Article “Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis” by Starvaggi Cucuzza et al.,¹ the first 2 sentences of the “B-Cell Data” section under the Methods should identify the total B cells and B memory cells as “(CD3⁻CD19⁺)” and “(CD3⁻CD19⁺CD27…),” respectively. It should read as follows:

Total B-cell (CD3⁻CD19⁺) levels were assessed by flow cytometry before each rituximab infusion, as per clinical routine, at the Department of Clinical Immunology, Karolinska University Hospital. B memory cell (CD3⁻CD19⁺CD27+immunoglobulin D (IgD)-, CD27⁺IgD⁺, and CD27⁻IgD⁻) percentages were determined in patients with detectable B cells and converted to absolute numbers using the extracted data.

The authors regret the error.